Serotonergic and dopaminergic neurons in the dorsal raphe are differentially altered in a mouse model for parkinsonism.
Laura BoiYvonne JohanssonRaffaella ToniniRosario MoratallaGilberto FisoneGilad SilberbergPublished in: eLife (2024)
Parkinson's disease (PD) is characterized by motor impairments caused by degeneration of dopamine neurons in the substantia nigra pars compacta. In addition to these symptoms, PD patients often suffer from non-motor comorbidities including sleep and psychiatric disturbances, which are thought to depend on concomitant alterations of serotonergic and noradrenergic transmission. A primary locus of serotonergic neurons is the dorsal raphe nucleus (DRN), providing brain-wide serotonergic input. Here, we identified electrophysiological and morphological parameters to classify serotonergic and dopaminergic neurons in the murine DRN under control conditions and in a PD model, following striatal injection of the catecholamine toxin, 6-hydroxydopamine (6-OHDA). Electrical and morphological properties of both neuronal populations were altered by 6-OHDA. In serotonergic neurons, most changes were reversed when 6-OHDA was injected in combination with desipramine, a noradrenaline (NA) reuptake inhibitor, protecting the noradrenergic terminals. Our results show that the depletion of both NA and dopamine in the 6-OHDA mouse model causes changes in the DRN neural circuitry.
Keyphrases
- spinal cord
- mouse model
- neuropathic pain
- end stage renal disease
- spinal cord injury
- escherichia coli
- chronic kidney disease
- ejection fraction
- parkinson disease
- newly diagnosed
- peritoneal dialysis
- white matter
- prognostic factors
- cerebral ischemia
- patient reported outcomes
- resting state
- ultrasound guided
- blood brain barrier
- patient reported